Floatz logo

Bxcl501

Postoperative Vomiting

Medical University of WarsawPhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Postoperative Vomiting cohort.

Asset / SponsorPhaseRating
LIDOCAINE
Medical University of Warsaw
Phase 4BB
RAMIFENTANYL
Medical University of Warsaw
Phase 4BB
FENTANYL
Medical University of Warsaw
Phase 4BB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Medical University of Warsaw
Phase 4BB
DEXAMETHASONE
Instituto Mexicano del Seguro Social
Phase 3B

Same molecule, other indications

Bxcl501 is also rated in:

Pain, ChronicDormant
A
Indicative ·
80 / 100
View asset →
Agitation,PsychomotorDormant
A
Indicative ·
80 / 100
View asset →
schizophreniform disorderDormant
A
Indicative ·
80 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →